January 24, 2019 10:52 AM EST

FDA opioid adcomm chair blasts agency for 'willful blindness that borders on the criminal'

Amber Tong

In scathing remarks directed at the FDA’s handling of opioid approvals, the head of the agency’s advisory panel has lambasted its “cozy, cozy relationships” with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA opioid adcomm chair blasts agency for 'willful blindness that borders on the criminal'

Amber Tong

Sign up to read this article for free.

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

FDA opi­oid ad­comm chair blasts agency for 'will­ful blind­ness that bor­ders on the crim­i­nal'

Amber Tong

Sign up to read this article for free.

more like this

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

FDA opioid adcomm chair blasts agency for 'willful blindness that borders on the criminal'

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months